Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CAR-T Meeting 2020 | CARCIK-CD19: allogeneic and non-viral CAR T-cells

Chiara Magnani • 30 Jan 2020
CAR-T Meeting 2020
Acute Lymphoblastic Leukemia Leukemia CAR-T

Chiara Magnani, PhD, University of Milano-Bicocca, Milan, Italy & Fondazione Tettamanti, Monza Italy, discusses the ongoing phase I/II trial on donor-derived CD19 CAR cytokine-induced killer (CIK) cells engineered with a sleeping beauty (SB) transposon for relapsed B-cell acute lymphoblastic leukemia (B-ALL). Dr Magnani outlines the manufacturing process and reveals that SB-engineered CARCIK-CD19 cells can expand and persist in pediatric and adult B-ALL patients who have relapsed after hematopoietic stem cell transplantation (HSCT). This interview took place at the 2nd European CAR T-Cell Meeting in Sitges, Spain.

More from Chiara Magnani

CAR T-cell therapy: the importance of donor-derived cells in treatment
2:15
CAR T-cell therapy: the importance of donor-derived cells in treatment
Chiara Magnani • 16 Dec 2021
CARCIK trial updates: using SB-engineered CAR-T cells in patients with B-ALL
4:22
CARCIK trial updates: using SB-engineered CAR-T cells in patients with B-ALL
Chiara Magnani • 16 Dec 2021
What is on the CAR-T horizon?
2:35
What is on the CAR-T horizon?
Chiara Magnani • 11 Dec 2020
Transposon-manipulated allogeneic CAR-T therapy for B-ALL
5:35
Transposon-manipulated allogeneic CAR-T therapy for B-ALL
Chiara Magnani • 11 Dec 2020

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals